President, North America
Kevin O’Brien serves as President of North America for Merz Therapeutics, where he leads commercial strategy and execution, including field sales, managed markets, medical affairs, marketing and operations, across the U.S. and Canada.
Mr. O’Brien understands the value of developing novel treatment options for neurological conditions and continually demonstrates Merz’s commitment to the movement disorder community through advocacy partnerships and awareness initiatives. Since joining Merz in 2017, he has overseen the U.S. FDA approval of Merz’s neuromodulator for the treatment of sialorrhea (excessive drooling) and as a first-line treatment for blepharospasm, two debilitating conditions associated with neurological conditions, including Parkinson’s disease, ALS and cerebral palsy.
Mr. O’Brien is a global healthcare executive with more than 30 years of experience leading teams and product launches in neurosciences, medical aesthetics, plastic surgery and dermatology. Prior to joining Merz, Mr. O’Brien spent more than 16 years at Allergan, most recently as Executive Director of Medical Aesthetics for Canada. At Allergan, Mr. O’Brien led global teams in the U.S., Canada and Asia Pacific, with a focus on China, Japan and Korea. Before Allergan, Mr. O’Brien had a successful career with J&J and Boston Scientific.
Mr. O’Brien received his juris doctor degree from Western State University and his bachelor’s degree from Saint Mary’s College of California.
Vice President, U.S. Marketing
Senior Director, Head of Human Resources and Communications
Director, Commercial Operations
Vice President, U.S. Sales
Country Manager, Merz Pharma Canada Ltd.
Director, Head of U.S. Regulatory Affairs
Senior Director, Head of Medical Affairs
Vice President, Managed Markets